Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Urinary tract obstruction

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    34 result(s) found for: Urinary tract obstruction. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2008-007353-12 Sponsor Protocol Number: FARM79BKPY Start Date*: 2007-05-29
    Sponsor Name:UNIVERSITA` DEGLI STUDI DI PARMA
    Full Title: METHOTREXATE AS STEROID-SPARING AGENT IN IDIOPATHIC RETROPERITONEAL FIBROSIS: A MULTICENTRE RANDOMISED CONTROLLED TRIAL
    Medical condition: Pazient affected by idiopathic retroperitoneal fibrosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10046587 Urinary tract obstruction NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-001268-57 Sponsor Protocol Number: 905-CL-058 Start Date*: 2007-09-12
    Sponsor Name:Astellas Pharma US, Inc.
    Full Title: A Phase 2, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multi-Center Study to Evaluate the Safety of the Co-administration of Solifenacin Succinate with 0.4 mg Tamsulosin Hydrochlo...
    Medical condition: Storage and Voiding Lower Urinary Tract Symptoms (LUTS) and Bladder Outlet Obstruction (BOO)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027561 Micturition disorder LLT
    9.1 10005053 Bladder neck obstruction LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: CZ (Completed) BE (Completed) HU (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-005912-41 Sponsor Protocol Number: TMO-07001 Start Date*: 2010-05-04
    Sponsor Name:Belpharma SA/NV
    Full Title: Temocillin use in Complicated Urinary Tract Infections due to ESBL producing and AmpC hyperproducing Enterobacteriaceae in United Kingdom
    Medical condition: Patients presenting urinary tract infections due to Extended Spectrum Beta-Lactamases producing or AmpC hyperproducing Enterobacteriaceae.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10046571 Urinary tract infection LLT
    9.1 10002737 Antibiotic resistant strain LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-002055-32 Sponsor Protocol Number: PSD506-OAB-004 Start Date*: 2006-10-09
    Sponsor Name:Plethora Solutions Limited
    Full Title: A double-blind, placebo controlled, pilot study to assess the safety and preliminary efficacy of PSD506 in treatment-naïve or previously treated (washed out) patients with benign prostatic obstruct...
    Medical condition: This study aims to assess the safety of PSD506 in men with benign prostatic enlargement (BPE) / benign prostatic obstruction (BPO) and lower urinary tract symptoms (LUTS) and an IPSS of 8-19, in li...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10055026 Prostatic obstruction LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Prematurely Ended) IE (Completed) GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-004380-58 Sponsor Protocol Number: A3711045 Start Date*: 2007-03-15
    Sponsor Name:Pfizer Limited
    Full Title: A MULTI-CENTER, RANDOMIZED, CROSS-OVER, DOUBLE-BLIND, THIRD PARTY OPEN, PLACEBO CONTROLLED, PILOT STUDY TO ASSESS THE URODYNAMIC EFFECTS OF MODIFIED RELEASE UK-369,003 IN MEN WITH LOWER URINARY TRA...
    Medical condition: Lower Urinary Tract Symptoms
    Disease: Version SOC Term Classification Code Term Level
    8.1 10024981 Lower urinary tract infection LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Completed) CZ (Completed) LV (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-015953-18 Sponsor Protocol Number: DORIPED3002 Start Date*: 2010-05-28
    Sponsor Name:Janssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium
    Full Title: A Prospective, Randomized, Double-Blind, Multicenter Study to Establish the Safety and Tolerability of Doripenem Compared With Cefepime in Hospitalized Children With Complicated Urinary Tract Infec...
    Medical condition: Complicated Urinary Tract Infections
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10046571 Urinary tract infection PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: LT (Prematurely Ended) CZ (Completed) PL (Temporarily Halted) LV (Prematurely Ended) DE (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2018-001451-13 Sponsor Protocol Number: VNRX-5133-201 Start Date*: 2019-07-02
    Sponsor Name:Venatorx Pharmaceuticals, Inc.
    Full Title: A Phase 3, Randomized, Double-blind, Active-controlled Noninferiority Study Evaluating the Efficacy, Safety, and Tolerability of Cefepime/VNRX-5133 in Adults with Complicated Urinary Tract Infecti...
    Medical condition: Complicated Urinary Tract Infections, Including Acute Pyelonephritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10046577 Urinary tract infections HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) CZ (Completed) HU (Completed) BG (Completed) HR (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2008-002151-25 Sponsor Protocol Number: D4260C00007 Start Date*: 2008-07-03
    Sponsor Name:AstraZeneca AB
    Full Title: A Double-Blind, Randomised, Placebo-Controlled, Parallel Group Multi-Centre Phase IIa Study to Assess the Effects on Biomarkers in Induced Sputum, Blood and Urine of AZD1236 Administered as Oral Ta...
    Medical condition: Chronic Obstructive Pulmonary Disease (study conducted in men or women, not of child bearing potential, aged 40 years or above).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) FI (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2004-001168-28 Sponsor Protocol Number: D5899C00001 Start Date*: 2005-01-04
    Sponsor Name:AstraZeneca AB
    Full Title: A 12-month, double-blind, double-dummy, randomized, parallel group, multicenter efficacy and safety study of Symbicort® pMDI 2x160/4.5μg bid and 2x80/4.5 μg bid compared to Formoterol Turbuhaler 2x...
    Medical condition: This is an application for a phase III study to be conducted in COPD patients.
    Disease: Version SOC Term Classification Code Term Level
    10010952
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) HU (Completed) IS (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2004-001183-41 Sponsor Protocol Number: D5899C00002 Start Date*: 2005-02-14
    Sponsor Name:AstraZeneca AB
    Full Title: A 6-month, double-blind, double-dummy, randomised, parallel group, multicenter, efficacy and safety study of Symbicort® pMDI 2x160/4.5μg and 2x80/4.5μg bid compared to Formoterol Turbuhaler, Budes...
    Medical condition: This is an application for a phase III study to be conducted in COPD patients.
    Disease: Version SOC Term Classification Code Term Level
    10010952
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2008-005909-19 Sponsor Protocol Number: PAW002 Start Date*: 2009-01-29
    Sponsor Name:The University of Dundee
    Full Title: Does extra fine HFA-BDP suppress small airways inflammation in COPD?
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010952 COPD LLT
    Population Age: Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-000643-95 Sponsor Protocol Number: CNVA237A2206 Start Date*: 2007-06-25
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, placebo controlled, parallel group, multi-center study, to assess the safety and tolerability of 28 days treatment with NVA237 (100 or 200µg once a day) in patients with...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10009033 Chronic obstructive pulmonary disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2007-004321-15 Sponsor Protocol Number: H6D-MC-LVHK(b) Start Date*: 2007-12-14
    Sponsor Name:Eli Lilly and Company Limited
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multicenter Study to Evaluate the Urodynamic Effects of Tadalafil Once a Day for 12 Weeks in Men With Signs and Symptoms of Benign P...
    Medical condition: Effects on urodynamic parameters in men with benign prostatic hyperplasia (also referred to as BPH-LUTS [lower urinary tract symptoms]) with and without urodynamic evidence of bladder outlet obstru...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10004446 Benign prostatic hyperplasia LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: PT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-000045-20 Sponsor Protocol Number: KMD 3213 IT-CL 0376 Start Date*: 2011-06-17
    Sponsor Name:RECORDATI S.p.A
    Full Title: Effectiveness and safety of silodosin in the treatment of LUTS in patients with benign prostatic hyperplasia: a European phase IV clinical study (the Silodosin in Real-life Evaluation study)
    Medical condition: Benign prostatic hyperplasia.
    Disease: Version SOC Term Classification Code Term Level
    13.1 10038604 - Reproductive system and breast disorders 10004446 Benign prostatic hyperplasia PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Completed) DE (Completed) IT (Completed) PT (Completed) HU (Completed) IE (Completed) ES (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2010-020604-29 Sponsor Protocol Number: H6D-CR-LVIW(a), Addendum 1 u.4 Start Date*: 2010-11-05
    Sponsor Name:Eli Lilly and Company Limited
    Full Title: A Phase 3b,randomized,double-blind,placebo-controlled parallel-design study to evaluate the efficacy and safety of tadalafil coadministered with finasteride for 6 months in men with lower urinary ...
    Medical condition: Benign Prostatic Hyperplasia (BPH)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10004446 Benign prostatic hyperplasia LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed) FR (Completed) BE (Completed) IT (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2012-003413-33 Sponsor Protocol Number: TBB-COPD-201 Start Date*: 2012-12-10
    Sponsor Name:Teva Branded Pharmaceutical Products R&D, Inc.
    Full Title: A Randomized, Open-Label, Repeat Dosing (7 days), Four-Period Crossover Study to Compare the Pharmacokinetics, Efficacy and Safety of Tiotropium Bromide Delivered via Breath Actuated Inhaler (BAI)...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    15.0 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-005544-10 Sponsor Protocol Number: NIHRCDF Start Date*: 2012-04-10
    Sponsor Name:Imperial College London
    Full Title: Improving Inhaler Treatment and Small Airways Assessment in Chronic Obstructive Pulmonary Disease
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    18.0 10042613 - Surgical and medical procedures 10052996 Inhalation therapy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-004883-12 Sponsor Protocol Number: ADA109057 Start Date*: 2016-12-08
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A 52-week, Randomized, Double-Blind, Parallel-Group Study of Fluticasone Propionate/Salmeterol DISKUS Combination Product (FSC) 250/50 mcg BID and Fluticasone Propionate (FP) DISKUS 250 mcg BID in ...
    Medical condition: Asthma
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2004-004149-16 Sponsor Protocol Number: H3E-ES-S085 Start Date*: 2005-02-16
    Sponsor Name:Lilly S.A.
    Full Title: Phase 1/2 Study of Biweekly ALIMTA plus Cisplatin in patients with Locally Advanced, non-Resectable or Metastatic Urothelial Cancer
    Medical condition: Locally Advanced, non-Resectable or Metastatic Urothelial Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2010-020220-22 Sponsor Protocol Number: H6D-MC-LVIR Start Date*: 2010-12-21
    Sponsor Name:Eli Lilly and Company
    Full Title: A Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Effect of Tadalafil Once Daily for 8 Weeks on Prostatic Blood Flow and Perfusion Parameters in Men with Signs and Symptoms of Be...
    Medical condition: Benign Prostatic Hyperplasia (BPH)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10038604 - Reproductive system and breast disorders 10004446 Benign prostatic hyperplasia PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: BE (Completed) AT (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 11 06:49:44 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA